 Zacks Investment Research upgraded shares of Delcath Systems OTCMKTS:DCTH from a sell rating to a hold rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, Delcath Systems, Inc. has developed a system, the Delcath system, to isolate the liver from the general circulatory system and to administer chemotherapy and other therapeutic ... 